Literature Review
Targeting the endocannabinoid system in migraine
Cannabis and other compounds that interact with the endocannabinoid system may be able to modulate the pathways involved in migraine-related pain...
Clinical Edge Journal Scan
Clinical Edge Journal Scan Commentary: Migraine March 2022
Literature Review
In-hospital detox or not, anti-CGRPs show efficacy for medication overuse headache
Current findings support the emerging evidence that anti-CGRP monoclonal antibodies may be effective in medication overuse headache patients...
Clinical Edge Journal Scan
Atogepant is safe and effective for episodic migraine prophylaxis
Clinical Edge Journal Scan
Impact of anti-CGRP mAb discontinuation and reinitiation in chronic migraine
Clinical Edge Journal Scan
Eptinezumab offers effective migraine treatment irrespective of patient baseline characteristics
Clinical Edge Journal Scan
Having migraine increases the risk of developing neovascular AMD
Clinical Edge Journal Scan
Dietary nutrient patterns may influence the intensity and duration of migraine headaches
Clinical Edge Journal Scan
Migraine negatively correlates with large artery atherosclerosis in ischemic stroke
Clinical Edge Journal Scan
Caffeine cessation beneficial in episodic migraine
Clinical Edge Journal Scan
Atorvastatin plus nortriptyline: A promising combination for migraine therapy
Clinical Edge Journal Scan
Rimegepant lowers MMDs and tablet use and improves HRQoL in migraine
Clinical Edge Journal Scan
Galcanezumab improves functioning and reduces disability in treatment-resistant migraine
Expert Perspective
Headache and Covid-19: What clinicians should know
Literature Review
PACAP38- and VIP-induced cluster headache attacks do not appear to alter CGRP levels
Is CGRP the missing link for patients who begin a cluster attack, or should we be looking elsewhere?